Meeting
2018 ASCO Annual Meeting
Phase I trial of the triplet M6620 (formerly VX970) + veliparib + cisplatin in patients with advanced solid tumors.
Authors
Geraldine Helen O'Sullivan Coyne
Early Clinical Trials Development Program, DCTD, National Cancer Institute at the National Institutes of Health, Bethesda, MD
Geraldine Helen O'Sullivan Coyne , Khanh Tu Do , Shivaani Kummar , Naoko Takebe , Mary Flanagan Quinn , Sarina Anne Piha-Paul , Ashley Bruns , Lamin Juwara , Elad Sharon , Richard Piekarz , Howard Streicher , Larry Rubinstein , Deborah Wilsker , Robert J. Kinders , Ralph E. Parchment , Elliot B Levy , Austin Doyle , James H. Doroshow , Alice P. Chen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics and Translational Research
Sub Track
Other Novel Agents
Clinical Trial Registration Number
NCT02723864
Citation
J Clin Oncol 36, 2018 (suppl; abstr 2549)
DOI
10.1200/JCO.2018.36.15_suppl.2549
Abstract #
2549
Poster Bd #
375
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Phase I trial of the triplet veliparib + VX-970 + cisplatin in patients with advanced solid tumors.
First Author: Geraldine Helen O'Sullivan Coyne
Poster
2022 ASCO Annual Meeting
A phase I trial of elimusertib in combination with cisplatin or with cisplatin plus gemcitabine in advanced solid tumors with an emphasis on urothelial carcinoma.
First Author: Ryan Leibrandt
Poster
2019 ASCO Annual Meeting
Safety and tolerability of veliparib, an oral PARP inhibitor, and M6620 (VX-970), an ATR inhibitor, in combination with cisplatin in patients with refractory solid tumors.
First Author: Arjun Mittra
Poster
2018 Gastrointestinal Cancers Symposium
A phase I study of veliparib (Vel) in combination with oxaliplatin (Ox) and capecitabine (Cap) in advanced solid tumors.
First Author: Anita Ahmed Turk